Search

Your search keyword '"Bander, Neil"' showing total 630 results
Start Over Author "Bander, Neil"
630 results on '"Bander, Neil"'

1. Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting

Author

Miyahira, Andrea K, Pienta, Kenneth J, Babich, John W, Bander, Neil H, Calais, Jeremie, Choyke, Peter, Hofman, Michael S, Larson, Steven M, Lin, Frank I, Morris, Michael J, Pomper, Martin G, Sandhu, Shahneen, Scher, Howard I, Tagawa, Scott T, Williams, Scott, and Soule, Howard R

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Urologic Diseases, Prostate Cancer, Aging, Cancer, Biomedical Imaging, Good Health and Well Being, Humans, Male, Molecular Targeted Therapy, Precision Medicine, Prostatic Neoplasms, Theranostic Nanomedicine, clinical trials, medical oncology, nuclear medicine, PET imaging, prostate-specific membrane antigen, radiation therapy, radiology, radionuclides, radiopharmaceuticals, urology, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

IntroductionThe Prostate Cancer Foundation (PCF) convened a PCF prostate-specific membrane antigen (PSMA) Theranostics State of the Science Meeting on 18 November 2019, at Weill Cornell Medicine, New York, NY.MethodsThe meeting was attended by 22 basic, translational, and clinical researchers from around the globe, with expertise in PSMA biology, development and use of PSMA theranostics agents, and clinical trials. The goal of this meeting was to discuss the current state of knowledge, the most important biological and clinical questions, and critical next steps for the clinical development of PSMA positron emission tomography (PET) imaging agents and PSMA-targeted radionuclide agents for patients with prostate cancer.ResultsSeveral major topic areas were discussed including the biology of PSMA, the role of PSMA-targeted PET imaging in prostate cancer, the physics and performance of different PSMA-targeted PET imaging agents, the current state of clinical development of PSMA-targeted radionuclide therapy (RNT) agents, the role of dosimetry in PSMA RNT treatment planning, barriers and challenges in PSMA RNT clinical development, optimization of patient selection for PSMA RNT trials, and promising combination treatment approaches with PSMA RNT.DiscussionThis article summarizes the presentations from the meeting for the purpose of globally disseminating this knowledge to advance the use of PSMA-targeted theranostic agents for imaging and treatment of patients with prostate cancer.

Published
2020

2. Final results of a phase I/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).

Author

Tagawa, Scott T., primary, Thomas, Charlene, additional, Nauseef, Jones T., additional, Sartor, A. Oliver, additional, Sun, Michael Philip, additional, Huicochea Castellanos, Sandra, additional, Ricaurte Fajardo, Andres, additional, Beltran, Himisha, additional, Demichelis, Francesca, additional, Sigouros, Michael, additional, Orlando, Francesco, additional, Molina, Ana M., additional, Davidson, Zachary, additional, Patel, Amie, additional, Lewis, Brian E., additional, Nanus, David M., additional, Vallabhajosula, Shankar, additional, Bander, Neil Harrison, additional, and Osborne, Joseph, additional

Published
2024
Full Text
View/download PDF

3. PD01-11 PHASE I DOSE-ESCALATION TRIAL OF MULTIPLE AND FRACTIONATED-DOSE PSMA-TARGETED ALPHA RADIONUCLIDE (225AC-J591) FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Author

Sun, Michael, primary, Nauseef, Jones, additional, Fajardo, Andrés Ricaurte, additional, Davidson, Zachary, additional, Thomas, Joseph, additional, Ruder, Samuel, additional, Stangl-Kremser, Judith, additional, Castellanos, Sandra Huicochea, additional, Molina, Ana, additional, Sternberg, Cora, additional, Patel, Amie, additional, Yuan, Sarah, additional, Fernandez, Escarleth, additional, Fung, Edward, additional, Avlonitis, Vasilios, additional, O'Dwyer, Elisabeth, additional, Nanus, David, additional, Osborne, Joseph, additional, Bander, Neil, additional, and Tagawa, Scott, additional

Published
2024
Full Text
View/download PDF

6. Prostatic irradiation-induced sexual dysfunction: a review and multidisciplinary guide to management in the radical radiotherapy era (Part I defining the organ at risk for sexual toxicities)

Author

Ramirez-Fort, Marigdalia K., Rogers, Marc J., Santiago, Roberto, Mahase, Sean S., Mendez, Melissa, Zheng, Yi, Kong, Xiang, Kashanian, James A., Niaz, M. Junaid, McClelland, Shearwood, III, Wu, Xiaodong, Bander, Neil H., Schlegel, Peter, Mulhall, John P., and Lange, Christopher S.

Published
2020
Full Text
View/download PDF

7. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma

Author

McNeel, Douglas G, Bander, Neil H, Beer, Tomasz M, Drake, Charles G, Fong, Lawrence, Harrelson, Stacey, Kantoff, Philip W, Madan, Ravi A, Oh, William K, Peace, David J, Petrylak, Daniel P, Porterfield, Hank, Sartor, Oliver, Shore, Neal D, Slovin, Susan F, Stein, Mark N, Vieweg, Johannes, and Gulley, James L

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Immunology, Urologic Diseases, Vaccine Related, Aging, Biotechnology, Prostate Cancer, Cancer, Immunization, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Guidelines, Immunotherapy, Treatment, Oncology and carcinogenesis
Abstract

Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being investigated in late-stage clinical trials for the management of advanced prostate cancer. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel, including physicians, nurses, and patient advocates, to develop consensus recommendations for the clinical application of immunotherapy for prostate cancer patients. To do so, a systematic literature search was performed to identify high-impact papers from 2006 until 2014 and was further supplemented with literature provided by the panel. Results from the consensus panel voting and discussion as well as the literature review were used to rate supporting evidence and generate recommendations for the use of immunotherapy in prostate cancer patients. Sipuleucel-T, an autologous dendritic cell vaccine, is the first and currently only immunotherapeutic agent approved for the clinical management of metastatic castrate resistant prostate cancer (mCRPC). The consensus panel utilized this model to discuss immunotherapy in the treatment of prostate cancer, issues related to patient selection, monitoring of patients during and post treatment, and sequence/combination with other anti-cancer treatments. Potential immunotherapies emerging from late-stage clinical trials are also discussed. As immunotherapy evolves as a therapeutic option for the treatment of prostate cancer, these recommendations will be updated accordingly.

Published
2016

9. Tumor Therapy with Targeted Atomic Nanogenerators

Author

McDevitt, Michael R., Ma, Dangshe, Lai, Lawrence T., Simon, Jim, Borchardt, Paul, Frank, R. Keith, Wu, Karen, Pellegrini, Virginia, Curcio, Michael J., Miederer, Matthias, Bander, Neil H., and Scheinberg, David A.

Published
2001

10. Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225 Ac-J591.

Author

Tagawa, Scott T., Thomas, Charlene, Sartor, A. Oliver, Sun, Michael, Stangl-Kremser, Judith, Bissassar, Mahelia, Vallabhajosula, Shankar, Castellanos, Sandra Huicochea, Nauseef, Jones T., Sternberg, Cora N., Molina, Ana, Ballman, Karla, Nanus, David M., Osborne, Joseph R., and Bander, Neil H.

Published
2024
Full Text
View/download PDF

13. α-Labeling of J591, an Antibody Targeting Prostate-Specific Membrane Antigen: The Technique and Considerations from the First Dedicated Production Lab at an Academic Institution in the United States

Author

Subramanian, Kritika, primary, Stangl-Kremser, Judith, additional, Sawoszczyk, Lady, additional, Avlonitis, Vasilios, additional, Gernerd, Andrew, additional, Nixon, Kyla, additional, Zgaljardic, Michael, additional, Tagawa, Scott, additional, Bander, Neil, additional, and Osborne, Joseph R., additional

Published
2023
Full Text
View/download PDF

14. Abstract CT014: Phase I dose-escalation study of fractionated dose 225Ac J591 for metastatic castration resistant prostate cancer

Author

Nauseef, Jones T., primary, Sun, Michael, additional, Thomas, Charlene, additional, Bissassar, Mahelia, additional, Fernandez, Escarleth, additional, Davidson, Zachary, additional, Patel, Amie, additional, Tan, Angela, additional, Chamberlain, Tessa A., additional, Earle, Kara, additional, Wunder, Rebecca, additional, Guervil, Sabrina, additional, Castellanos, Sandra H., additional, Stangl-Kremser, Judith, additional, Gregos, Peter S., additional, Osborne, Joseph R., additional, Ballman, Karla V., additional, Molina, Ana M., additional, Sternberg, Cora N., additional, Nanus, David M., additional, Bander, Neil H., additional, and Tagawa, Scott T., additional

Published
2023
Full Text
View/download PDF

16. Data from Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer

Author

Cho, Song, primary, Zammarchi, Francesca, primary, Williams, David G., primary, Havenith, Carin E.G., primary, Monks, Noel R., primary, Tyrer, Peter, primary, D'Hooge, Francois, primary, Fleming, Ryan, primary, Vashisht, Kapil, primary, Dimasi, Nazzareno, primary, Bertelli, Francois, primary, Corbett, Simon, primary, Adams, Lauren, primary, Reinert, Halla W., primary, Dissanayake, Sandamali, primary, Britten, Charles E., primary, King, Wanda, primary, Dacosta, Karma, primary, Tammali, Ravinder, primary, Schifferli, Kevin, primary, Strout, Patrick, primary, Korade, Martin, primary, Masson Hinrichs, Mary Jane, primary, Chivers, Simon, primary, Corey, Eva, primary, Liu, He, primary, Kim, Sae, primary, Bander, Neil H., primary, Howard, Philip W., primary, Hartley, John A., primary, Coats, Steve, primary, Tice, David A., primary, Herbst, Ronald, primary, and van Berkel, Patrick H., primary

Published
2023
Full Text
View/download PDF

17. Table S1 from Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation

Author

Leconet, Wilhem, primary, Liu, He, primary, Guo, Ming, primary, Le Lamer-Déchamps, Sophie, primary, Molinier, Charlotte, primary, Kim, Sae, primary, Vrlinic, Tjasa, primary, Oster, Murielle, primary, Liu, Fang, primary, Navarro, Vicente, primary, Batra, Jaspreet S., primary, Noriega, Adolfo Lopez, primary, Grizot, Sylvestre, primary, and Bander, Neil H., primary

Published
2023
Full Text
View/download PDF

18. Data from Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer

Author

Miyamoto, David T., primary, Lee, Richard J., primary, Stott, Shannon L., primary, Ting, David T., primary, Wittner, Ben S., primary, Ulman, Matthew, primary, Smas, Malgorzata E., primary, Lord, Jenna B., primary, Brannigan, Brian W., primary, Trautwein, Julie, primary, Bander, Neil H., primary, Wu, Chin-Lee, primary, Sequist, Lecia V., primary, Smith, Matthew R., primary, Ramaswamy, Sridhar, primary, Toner, Mehmet, primary, Maheswaran, Shyamala, primary, and Haber, Daniel A., primary

Published
2023
Full Text
View/download PDF

19. Supplementary Methods from Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer

Author

Cho, Song, primary, Zammarchi, Francesca, primary, Williams, David G., primary, Havenith, Carin E.G., primary, Monks, Noel R., primary, Tyrer, Peter, primary, D'Hooge, Francois, primary, Fleming, Ryan, primary, Vashisht, Kapil, primary, Dimasi, Nazzareno, primary, Bertelli, Francois, primary, Corbett, Simon, primary, Adams, Lauren, primary, Reinert, Halla W., primary, Dissanayake, Sandamali, primary, Britten, Charles E., primary, King, Wanda, primary, Dacosta, Karma, primary, Tammali, Ravinder, primary, Schifferli, Kevin, primary, Strout, Patrick, primary, Korade, Martin, primary, Masson Hinrichs, Mary Jane, primary, Chivers, Simon, primary, Corey, Eva, primary, Liu, He, primary, Kim, Sae, primary, Bander, Neil H., primary, Howard, Philip W., primary, Hartley, John A., primary, Coats, Steve, primary, Tice, David A., primary, Herbst, Ronald, primary, and van Berkel, Patrick H., primary

Published
2023
Full Text
View/download PDF

20. Data from Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation

Author

Leconet, Wilhem, primary, Liu, He, primary, Guo, Ming, primary, Le Lamer-Déchamps, Sophie, primary, Molinier, Charlotte, primary, Kim, Sae, primary, Vrlinic, Tjasa, primary, Oster, Murielle, primary, Liu, Fang, primary, Navarro, Vicente, primary, Batra, Jaspreet S., primary, Noriega, Adolfo Lopez, primary, Grizot, Sylvestre, primary, and Bander, Neil H., primary

Published
2023
Full Text
View/download PDF

21. Supplementary Tables S1 to S4 from Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer

Author

Cho, Song, primary, Zammarchi, Francesca, primary, Williams, David G., primary, Havenith, Carin E.G., primary, Monks, Noel R., primary, Tyrer, Peter, primary, D'Hooge, Francois, primary, Fleming, Ryan, primary, Vashisht, Kapil, primary, Dimasi, Nazzareno, primary, Bertelli, Francois, primary, Corbett, Simon, primary, Adams, Lauren, primary, Reinert, Halla W., primary, Dissanayake, Sandamali, primary, Britten, Charles E., primary, King, Wanda, primary, Dacosta, Karma, primary, Tammali, Ravinder, primary, Schifferli, Kevin, primary, Strout, Patrick, primary, Korade, Martin, primary, Masson Hinrichs, Mary Jane, primary, Chivers, Simon, primary, Corey, Eva, primary, Liu, He, primary, Kim, Sae, primary, Bander, Neil H., primary, Howard, Philip W., primary, Hartley, John A., primary, Coats, Steve, primary, Tice, David A., primary, Herbst, Ronald, primary, and van Berkel, Patrick H., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Methods from Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer

Author

Miyamoto, David T., primary, Lee, Richard J., primary, Stott, Shannon L., primary, Ting, David T., primary, Wittner, Ben S., primary, Ulman, Matthew, primary, Smas, Malgorzata E., primary, Lord, Jenna B., primary, Brannigan, Brian W., primary, Trautwein, Julie, primary, Bander, Neil H., primary, Wu, Chin-Lee, primary, Sequist, Lecia V., primary, Smith, Matthew R., primary, Ramaswamy, Sridhar, primary, Toner, Mehmet, primary, Maheswaran, Shyamala, primary, and Haber, Daniel A., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Tables 1-2 from Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer

Author

Miyamoto, David T., primary, Lee, Richard J., primary, Stott, Shannon L., primary, Ting, David T., primary, Wittner, Ben S., primary, Ulman, Matthew, primary, Smas, Malgorzata E., primary, Lord, Jenna B., primary, Brannigan, Brian W., primary, Trautwein, Julie, primary, Bander, Neil H., primary, Wu, Chin-Lee, primary, Sequist, Lecia V., primary, Smith, Matthew R., primary, Ramaswamy, Sridhar, primary, Toner, Mehmet, primary, Maheswaran, Shyamala, primary, and Haber, Daniel A., primary

Published
2023
Full Text
View/download PDF

24. Figure S1 from Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation

Author

Leconet, Wilhem, primary, Liu, He, primary, Guo, Ming, primary, Le Lamer-Déchamps, Sophie, primary, Molinier, Charlotte, primary, Kim, Sae, primary, Vrlinic, Tjasa, primary, Oster, Murielle, primary, Liu, Fang, primary, Navarro, Vicente, primary, Batra, Jaspreet S., primary, Noriega, Adolfo Lopez, primary, Grizot, Sylvestre, primary, and Bander, Neil H., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figures 1-6 from Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer

Author

Miyamoto, David T., primary, Lee, Richard J., primary, Stott, Shannon L., primary, Ting, David T., primary, Wittner, Ben S., primary, Ulman, Matthew, primary, Smas, Malgorzata E., primary, Lord, Jenna B., primary, Brannigan, Brian W., primary, Trautwein, Julie, primary, Bander, Neil H., primary, Wu, Chin-Lee, primary, Sequist, Lecia V., primary, Smith, Matthew R., primary, Ramaswamy, Sridhar, primary, Toner, Mehmet, primary, Maheswaran, Shyamala, primary, and Haber, Daniel A., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figures S1-S7 from Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer

Author

Cho, Song, primary, Zammarchi, Francesca, primary, Williams, David G., primary, Havenith, Carin E.G., primary, Monks, Noel R., primary, Tyrer, Peter, primary, D'Hooge, Francois, primary, Fleming, Ryan, primary, Vashisht, Kapil, primary, Dimasi, Nazzareno, primary, Bertelli, Francois, primary, Corbett, Simon, primary, Adams, Lauren, primary, Reinert, Halla W., primary, Dissanayake, Sandamali, primary, Britten, Charles E., primary, King, Wanda, primary, Dacosta, Karma, primary, Tammali, Ravinder, primary, Schifferli, Kevin, primary, Strout, Patrick, primary, Korade, Martin, primary, Masson Hinrichs, Mary Jane, primary, Chivers, Simon, primary, Corey, Eva, primary, Liu, He, primary, Kim, Sae, primary, Bander, Neil H., primary, Howard, Philip W., primary, Hartley, John A., primary, Coats, Steve, primary, Tice, David A., primary, Herbst, Ronald, primary, and van Berkel, Patrick H., primary

Published
2023
Full Text
View/download PDF

27. MP29-10 PROGNOSTIC VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) RECEIVING PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETED RADIONUCLIDE THERAPY (TRT)

Author

Stangl-Kremser, Judith, primary, Sun, Michael, additional, Ho, Benedict, additional, Thomas, Joseph, additional, Nauseef, Jones, additional, Osborne, Joseph, additional, Molina, Ana, additional, Sternberg, Cora, additional, Nanus, David, additional, Bander, Neil, additional, and Tagawa, Scott, additional

Published
2023
Full Text
View/download PDF

28. Targeted Radionuclide Therapy of Prostate Cancer

Author

Goldsmith, Stanley J., Tagawa, Scott T., Vallabhajosula, Shankar, Nikolopoulou, Anastasia, Lipai, Irina, Bander, Neil H., Brady, Luther W., Series editor, Lu, Jiade J., Series editor, Nieder, Carsten, Series editor, and Baum, Richard P., editor

Published
2014
Full Text
View/download PDF

31. Supplementary Figures S1-4 from A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer

Author

Pandit-Taskar, Neeta, primary, O'Donoghue, Joseph A., primary, Durack, Jeremy C., primary, Lyashchenko, Serge K., primary, Cheal, Sarah M., primary, Beylergil, Volkan, primary, Lefkowitz, Robert A., primary, Carrasquillo, Jorge A., primary, Martinez, Danny F., primary, Fung, Alex Mak, primary, Solomon, Stephen B., primary, Gönen, Mithat, primary, Heller, Glenn, primary, Loda, Massimo, primary, Nanus, David M., primary, Tagawa, Scott T., primary, Feldman, Jarett L., primary, Osborne, Joseph R., primary, Lewis, Jason S., primary, Reuter, Victor E., primary, Weber, Wolfgang A., primary, Bander, Neil H., primary, Scher, Howard I., primary, Larson, Steven M., primary, and Morris, Michael J., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure Legend from Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer

Author

Tagawa, Scott T., primary, Milowsky, Matthew I., primary, Morris, Michael, primary, Vallabhajosula, Shankar, primary, Christos, Paul, primary, Akhtar, Naveed H., primary, Osborne, Joseph, primary, Goldsmith, Stanley J., primary, Larson, Steve, primary, Taskar, Neeta Pandit, primary, Scher, Howard I., primary, Bander, Neil H., primary, and Nanus, David M., primary

Published
2023
Full Text
View/download PDF

33. CCR Translation for This Article from Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer

Author

Tagawa, Scott T., primary, Milowsky, Matthew I., primary, Morris, Michael, primary, Vallabhajosula, Shankar, primary, Christos, Paul, primary, Akhtar, Naveed H., primary, Osborne, Joseph, primary, Goldsmith, Stanley J., primary, Larson, Steve, primary, Taskar, Neeta Pandit, primary, Scher, Howard I., primary, Bander, Neil H., primary, and Nanus, David M., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figure 1 from Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer

Author

Tagawa, Scott T., primary, Milowsky, Matthew I., primary, Morris, Michael, primary, Vallabhajosula, Shankar, primary, Christos, Paul, primary, Akhtar, Naveed H., primary, Osborne, Joseph, primary, Goldsmith, Stanley J., primary, Larson, Steve, primary, Taskar, Neeta Pandit, primary, Scher, Howard I., primary, Bander, Neil H., primary, and Nanus, David M., primary

Published
2023
Full Text
View/download PDF

35. Supplementary Video 2 from Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer

Author

Darshan, Medha S., primary, Loftus, Matthew S., primary, Thadani-Mulero, Maria, primary, Levy, Benjamin P., primary, Escuin, Daniel, primary, Zhou, Xi Kathy, primary, Gjyrezi, Ada, primary, Chanel-Vos, Chantal, primary, Shen, Ruoqian, primary, Tagawa, Scott T., primary, Bander, Neil H., primary, Nanus, David M., primary, and Giannakakou, Paraskevi, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Figure Legend from Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer

Author

Darshan, Medha S., primary, Loftus, Matthew S., primary, Thadani-Mulero, Maria, primary, Levy, Benjamin P., primary, Escuin, Daniel, primary, Zhou, Xi Kathy, primary, Gjyrezi, Ada, primary, Chanel-Vos, Chantal, primary, Shen, Ruoqian, primary, Tagawa, Scott T., primary, Bander, Neil H., primary, Nanus, David M., primary, and Giannakakou, Paraskevi, primary

Published
2023
Full Text
View/download PDF

37. Data from Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer

Author

Darshan, Medha S., primary, Loftus, Matthew S., primary, Thadani-Mulero, Maria, primary, Levy, Benjamin P., primary, Escuin, Daniel, primary, Zhou, Xi Kathy, primary, Gjyrezi, Ada, primary, Chanel-Vos, Chantal, primary, Shen, Ruoqian, primary, Tagawa, Scott T., primary, Bander, Neil H., primary, Nanus, David M., primary, and Giannakakou, Paraskevi, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure 1 from Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer

Author

Darshan, Medha S., primary, Loftus, Matthew S., primary, Thadani-Mulero, Maria, primary, Levy, Benjamin P., primary, Escuin, Daniel, primary, Zhou, Xi Kathy, primary, Gjyrezi, Ada, primary, Chanel-Vos, Chantal, primary, Shen, Ruoqian, primary, Tagawa, Scott T., primary, Bander, Neil H., primary, Nanus, David M., primary, and Giannakakou, Paraskevi, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Video 1 from Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer

Author

Darshan, Medha S., primary, Loftus, Matthew S., primary, Thadani-Mulero, Maria, primary, Levy, Benjamin P., primary, Escuin, Daniel, primary, Zhou, Xi Kathy, primary, Gjyrezi, Ada, primary, Chanel-Vos, Chantal, primary, Shen, Ruoqian, primary, Tagawa, Scott T., primary, Bander, Neil H., primary, Nanus, David M., primary, and Giannakakou, Paraskevi, primary

Published
2023
Full Text
View/download PDF

40. Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer

Author

Sayar, Erolcan, primary, Patel, Radhika A., additional, Coleman, Ilsa M., additional, Roudier, Martine P., additional, Zhang, Ailin, additional, Mustafi, Pallabi, additional, Low, Jin-Yih, additional, Hanratty, Brian, additional, Ang, Lisa S., additional, Bhatia, Vipul, additional, Adil, Mohamed, additional, Bakbak, Hasim, additional, Quigley, David A., additional, Schweizer, Michael T., additional, Hawley, Jessica E., additional, Kollath, Lori, additional, True, Lawrence D., additional, Feng, Felix Y., additional, Bander, Neil H., additional, Corey, Eva, additional, Lee, John K., additional, Morrissey, Colm, additional, Gulati, Roman, additional, Nelson, Peter S., additional, and Haffner, Michael C., additional

Published
2023
Full Text
View/download PDF

41. A phase I/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC) in patients with prior treatment with 177Lu-PSMA.

Author

Nauseef, Jones T., primary, Sun, Michael Philip, additional, Thomas, Charlene, additional, Bissassar, Mahelia, additional, Patel, Amie, additional, Tan, Angela, additional, Fernandez, Escarleth, additional, Davidson, Zachary, additional, Chamberlain, Tessa, additional, Earle, Kara, additional, Wunder, Rebecca, additional, Huicochea Castellanos, Sandra, additional, Gregos, Peter, additional, Osborne, Joseph, additional, Ballman, Karla V., additional, Molina, Ana M., additional, Sternberg, Cora N., additional, Nanus, David M., additional, Bander, Neil Harrison, additional, and Tagawa, Scott T., additional

Published
2023
Full Text
View/download PDF

42. Phase I results of a phase I/II study of pembrolizumab and AR signaling inhibitor (ARSI) with 225Ac-J591.

Author

Sun, Michael Philip, primary, Nauseef, Jones T., additional, Palmer, Jessica, additional, Thomas, Joseph Earl, additional, Stangl-Kremser, Judith, additional, Bissassar, Mahelia, additional, Huicochea Castellanos, Sandra, additional, Osborne, Joseph, additional, Molina, Ana M., additional, Sternberg, Cora N., additional, Nanus, David M., additional, Bander, Neil Harrison, additional, and Tagawa, Scott T., additional

Published
2023
Full Text
View/download PDF

43. Increased utilization of prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (PSMA-TRT) in African American (AA) patients at an academic medical center.

Author

Thomas, Joseph Earl, primary, Nauseef, Jones T., additional, Sun, Michael Philip, additional, Patel, Amie, additional, Tan, Angela, additional, Bissassar, Mahelia, additional, Manohar, Jyothi, additional, Subramanian, Kritika, additional, Amankwah, Koby, additional, Madera, Gabriela, additional, Molina, Ana M., additional, Sternberg, Cora N., additional, Nanus, David M., additional, Bander, Neil Harrison, additional, and Tagawa, Scott T., additional

Published
2023
Full Text
View/download PDF

44. Radioimmunotherapy of Prostate Carcinoma

Author

Goldsmith, Stanley J., Tagawa, Scott T., Vallabhajosula, Shankar, Nikolopoulou, Anastasia, Lipai, Irina, Nanus, David M., Bander, Neil H., Aktolun, Cumali, editor, and Goldsmith, Stanley J., editor

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results